INDGN
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Indegene climbs; Kotak raises fair value
** Shares of Indegene INEG.NS gain 1.4% to 591.6 rupees; stock rose as much as 3.5% on the day
** Brokerage Kotak Institutional Equities hikes fair value by 6% to 700 rupees, a Street-high; keeps "buy" rating
** Says growth recovery for FY26 is on track, tariffs uncertainties have not impacted demand significantly
** INEG provides digital services in the biopharma industry; major chunk of its revenue comes from North America
** Kotak expects co to deliver double-digit revenue growth in FY26, backed by strong deals pipeline, better industry outlook and lower client-specific headwinds
** Stock rated "hold" on avg, median PT is 610 rupees - data compiled by LSEG
** INEG down ~2% year-to-date
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of Indegene INEG.NS gain 1.4% to 591.6 rupees; stock rose as much as 3.5% on the day
** Brokerage Kotak Institutional Equities hikes fair value by 6% to 700 rupees, a Street-high; keeps "buy" rating
** Says growth recovery for FY26 is on track, tariffs uncertainties have not impacted demand significantly
** INEG provides digital services in the biopharma industry; major chunk of its revenue comes from North America
** Kotak expects co to deliver double-digit revenue growth in FY26, backed by strong deals pipeline, better industry outlook and lower client-specific headwinds
** Stock rated "hold" on avg, median PT is 610 rupees - data compiled by LSEG
** INEG down ~2% year-to-date
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
Indegene Announces Launch Of A New Center In London
March 19 (Reuters) - Indegene Ltd INEG.NS:
ANNOUNCED LAUNCH OF A NEW CENTER IN LONDON
Source text: [ID:]
Further company coverage: INEG.NS
(([email protected];;))
March 19 (Reuters) - Indegene Ltd INEG.NS:
ANNOUNCED LAUNCH OF A NEW CENTER IN LONDON
Source text: [ID:]
Further company coverage: INEG.NS
(([email protected];;))
Indegene Expands Footprint In Europe, Launches New Entity In Spain
Feb 6 (Reuters) - Indegene Ltd INEG.NS:
EXPANDS FOOTPRINT IN EUROPE, LAUNCHES NEW ENTITY IN SPAIN
Source text: [ID:]
Further company coverage: INEG.NS
(([email protected];;))
Feb 6 (Reuters) - Indegene Ltd INEG.NS:
EXPANDS FOOTPRINT IN EUROPE, LAUNCHES NEW ENTITY IN SPAIN
Source text: [ID:]
Further company coverage: INEG.NS
(([email protected];;))
Indegene Dec-Quarter Consol Net Profit 1.10 Bln Rupees
Jan 30 (Reuters) - Indegene Ltd INEG.NS:
DEC-QUARTER CONSOL NET PROFIT 1.10 BILLION RUPEES
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 7.20 BILLION RUPEES
Source text: ID:nBSE1YCKyg
Further company coverage: INEG.NS
(([email protected];;))
Jan 30 (Reuters) - Indegene Ltd INEG.NS:
DEC-QUARTER CONSOL NET PROFIT 1.10 BILLION RUPEES
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 7.20 BILLION RUPEES
Source text: ID:nBSE1YCKyg
Further company coverage: INEG.NS
(([email protected];;))
Indegene Says Cliniops Announces Strategic Partnership With Co
Jan 9 (Reuters) - Indegene Ltd INEG.NS:
INDEGENE LTD - CLINIOPS ANNOUNCES STRATEGIC PARTNERSHIP WITH INDEGENE
Source text: ID:nNSE4bq01s
Further company coverage: INEG.NS
(([email protected];))
Jan 9 (Reuters) - Indegene Ltd INEG.NS:
INDEGENE LTD - CLINIOPS ANNOUNCES STRATEGIC PARTNERSHIP WITH INDEGENE
Source text: ID:nNSE4bq01s
Further company coverage: INEG.NS
(([email protected];))
Indegene Says Sept-Quarter Consol Net Profit At 917 Million Rupees
Oct 28 (Reuters) - Indegene Ltd INEG.NS:
INDEGENE LTD SEPT-QUARTER CONSOL NET PROFIT 917 MILLION RUPEES
INDEGENE LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.87 BILLION RUPEES
Source text: ID:nNSE7skXTS
Further company coverage: INEG.NS
(([email protected];))
Oct 28 (Reuters) - Indegene Ltd INEG.NS:
INDEGENE LTD SEPT-QUARTER CONSOL NET PROFIT 917 MILLION RUPEES
INDEGENE LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.87 BILLION RUPEES
Source text: ID:nNSE7skXTS
Further company coverage: INEG.NS
(([email protected];))
Indegene June-Quarter Consol Net Profit 877 Million Rupees
Aug 1 (Reuters) - Indegene Ltd INEG.NS:
JUNE-QUARTER CONSOL NET PROFIT 877 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.77 BILLION RUPEES
Source text for Eikon: ID:nBSE9v5nfj
Further company coverage: INEG.NS
(([email protected];))
Aug 1 (Reuters) - Indegene Ltd INEG.NS:
JUNE-QUARTER CONSOL NET PROFIT 877 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.77 BILLION RUPEES
Source text for Eikon: ID:nBSE9v5nfj
Further company coverage: INEG.NS
(([email protected];))
India's Indegene rises on partnership with Microsoft
** Shares of Indegene Ltd INEG.NS rise as much as 3.5% to 589.90 rupees
** INEG, which provides medical commercialization services to pharma firms, announces partnership with Microsoft MSFT.O to help companies scale up the adoption of Generative AI
** Stock on track to gain for third straight day
** More than 1.5 mln shares traded as of 11:57 a.m. IST vs 30-day avg of 870,643 shares, highest vols in nearly a month
** INEG last up 2.7%, stock has gained ~2.4% since listing in May
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
** Shares of Indegene Ltd INEG.NS rise as much as 3.5% to 589.90 rupees
** INEG, which provides medical commercialization services to pharma firms, announces partnership with Microsoft MSFT.O to help companies scale up the adoption of Generative AI
** Stock on track to gain for third straight day
** More than 1.5 mln shares traded as of 11:57 a.m. IST vs 30-day avg of 870,643 shares, highest vols in nearly a month
** INEG last up 2.7%, stock has gained ~2.4% since listing in May
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
India's Indegene jumps in debut trade
** Shares of Indegene INEG.NS rise 44.9% in trading debut vs IPO price of 452 rupees
** INEG, provider of digital services for biopharma industry, opens at 655 rupees, stock so far above IPO price
** INEG currently up 27.3% at 137.64 bln rupees ($1.65 bln) valuation
** "Indegene defied market negativity with a spectacular debut on stock exchanges in line with expectations of premium between 40-50%" - Shivani Nyati, head of wealth at Swastika Investmart
** Broader market declines on concerns over outcome of ongoing national elections, sustained selling by foreign investors .BO
** INEG raised 18.42 bln rupees ($220.6 mln) in IPO which had fresh issue of shares worth 7.60 bln rupees, offer for sale of shares worth 10.82 bln rupees - prospectus
** IPO oversubscribed 69.91x last week - exchange data
($1 = 83.5125 Indian rupees)
(Reporting by Rama Venkat in Bengaluru)
** Shares of Indegene INEG.NS rise 44.9% in trading debut vs IPO price of 452 rupees
** INEG, provider of digital services for biopharma industry, opens at 655 rupees, stock so far above IPO price
** INEG currently up 27.3% at 137.64 bln rupees ($1.65 bln) valuation
** "Indegene defied market negativity with a spectacular debut on stock exchanges in line with expectations of premium between 40-50%" - Shivani Nyati, head of wealth at Swastika Investmart
** Broader market declines on concerns over outcome of ongoing national elections, sustained selling by foreign investors .BO
** INEG raised 18.42 bln rupees ($220.6 mln) in IPO which had fresh issue of shares worth 7.60 bln rupees, offer for sale of shares worth 10.82 bln rupees - prospectus
** IPO oversubscribed 69.91x last week - exchange data
($1 = 83.5125 Indian rupees)
(Reporting by Rama Venkat in Bengaluru)
Events:
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Indegene do?
Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for purpose technology.
Who are the competitors of Indegene?
Indegene major competitors are Syngene Internation., Jubilant Pharmova, Sanofi India, Dr. Agarwal's Health, Blue Jet Healthcare, Alivus Life Sciences, Granules India. Market Cap of Indegene is ₹13,661 Crs. While the median market cap of its peers are ₹14,252 Crs.
Is Indegene financially stable compared to its competitors?
Indegene seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Indegene pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Indegene latest dividend payout ratio is 11.78% and 3yr average dividend payout ratio is 11.78%
How has Indegene allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Indegene balance sheet?
Balance sheet of Indegene is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Indegene improving?
Yes, profit is increasing. The profit of Indegene is ₹407 Crs for Mar 2025, ₹337 Crs for Mar 2024 and ₹266 Crs for Mar 2023
Is the debt of Indegene increasing or decreasing?
The net debt of Indegene is decreasing. Latest net debt of Indegene is -₹749.2 Crs as of Mar-25. This is less than Mar-24 when it was ₹21.1 Crs.
Is Indegene stock expensive?
Indegene is not expensive. Latest PE of Indegene is 33.59, while 3 year average PE is 41.29. Also latest EV/EBITDA of Indegene is 24.87 while 3yr average is 28.64.
Has the share price of Indegene grown faster than its competition?
Indegene has given lower returns compared to its competitors. Indegene has grown at ~3.22% over the last 1yrs while peers have grown at a median rate of 10.0%
Is the promoter bullish about Indegene?
There is Insufficient data to gauge this.
Are mutual funds buying/selling Indegene?
The mutual fund holding of Indegene is increasing. The current mutual fund holding in Indegene is 2.65% while previous quarter holding is 1.64%.